<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC"><gtr:id>AE0A6EFE-F5FF-4B1D-A2C6-C1E6DEB6B1CC</gtr:id><gtr:name>Johannes Gutenberg University of Mainz</gtr:name><gtr:address><gtr:line1>University of Mainz</gtr:line1><gtr:line4>Mainz</gtr:line4><gtr:postCode>D-55099</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4F6D5C16-9376-4E97-BEA0-72DE59AB77C9"><gtr:id>4F6D5C16-9376-4E97-BEA0-72DE59AB77C9</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Wills</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/340C86AC-7DFE-4531-B18E-2D2AEE735A1E"><gtr:id>340C86AC-7DFE-4531-B18E-2D2AEE735A1E</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:surname>Sissons</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BBD65048-AED3-4824-ACD7-DEA6923DA9C3"><gtr:id>BBD65048-AED3-4824-ACD7-DEA6923DA9C3</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Sinclair</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701279"><gtr:id>70B35BE6-AC12-4BAA-BA13-3D3DF42BCF11</gtr:id><gtr:title>Human cytomegalovirus latency, reactivation and immune control</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701279</gtr:grantReference><gtr:abstractText>Human cytomegalovirus (HCMV) is a virus which is carried without symptoms by the majority of the population. However, it can cause serious disease in infants born to mothers who acquire the infection in pregnancy and in people whose immune system is suppressed. Understanding how the virus succeeds in maintaining itself in most people without causing disease and how this relationship breaks down to cause disease should help develop better methods of treating the virus and of designing a vaccine (there is currently no vaccine available). Our research is aimed at determining (i) the mechanism by which the virus maintains silent infection (latency) in specialised cells of the immune system and the factors that reawake it and (ii) how the immune system controls the infection in normal people. In addition to advancing our understanding of HCMV in particular, this research may also lead to a better understanding of other virus infections which persist in the body, and how the human host controls them.</gtr:abstractText><gtr:technicalSummary>Abstract
This programme of research focuses on human cytomegalovirus (HCMV), a ubiquitous human herpesvirus which is a major cause of morbidity, especially in the immunocompromised host. Our previous work using models of both natural and experimental latency has shown that dendritic cells, key antigen-presenting cells, are an important site of HCMV latency and reactivation. In this programme of research we propose to use these models to address the following questions which we believe are crucial to understanding HCMV latency, reactivation and immune control.
We will identify viral latency-associated transcripts in natural latency in myeloid lineage cells from healthy HCMV carriers and determine how latency-associated genes are regulated in undifferentiated and differentiated myeloid cells. We will also analyse the function of specific latency-associated transcripts which we have already identified in CD34+ progenitors of healthy HCMV carriers, and determine if these are recognised by the CD8+ T cell response and also determine if T cell specificity for individual HCMV proteins is important for control of reactivation and dissemination.
HCMV-mediated changes in cellular gene expression, during infection of permissive cells, have profound effects on numerous cellular functions but little is known about virus-induced changes in cellular gene expression during latency and reactivation. Consequently, we will compare changes in cellular gene expression associated with latency and reactivation of HCMV and analyse what role these changes may play in virus persistence and determine whether they aid avoidance of immune surveillance.
As there is a high frequency of HCMV-specific revertant memory T cells maintained in virus carriers, which suggests that they are crucial for immune control, we will determine the requirements for activation of these memory T cells and also determine whether they play a particular role in detecting viral reactivation and preventing viral dissemination. Finally, we will determine the phenotype, antigen specificity, activation status, cytokine profile and clonality of T cells recruited to natural sites of reactivation in vivo.
The work proposed will address fundamental questions about the molecular interactions between the virus and the cell which maintain latency and permit reactivation in vivo, and how the immune response then limits virus dissemination. The resultant increased understanding of virus pathogenesis at the level of specific viral gene products and host immune responses, should lead to rational methods of therapeutic intervention, such as novel antiviral strategies and approaches to vaccines.</gtr:technicalSummary><gtr:fund><gtr:end>2013-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1678954</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>proteomics analyses of latency-associated HCMV genes</gtr:description><gtr:id>94A0DA0D-07BD-4085-BE8F-A8EBC8269D06</gtr:id><gtr:impact>Weekes, M.P, Tan SY, Poole E, Talbot S, Antrobus R, Smith DL, Montag C, Gygi SP, Sinclair JH, Lehner PJ. (2013) Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science 340, 199-202.
Karniely S, Weekes MP, Antrobus R, Rorbach J, van Haute L, Umrania Y, Smith DL, Stanton RJ, Minczuk M, Lehner PJ, Sinclair JH. 2016. Human Cytomegalovirus Infection Upregulates the Mitochondrial Transcription and Translation Machineries. MBio 7</gtr:impact><gtr:outcomeId>h1ppmiHwVJ3-1</gtr:outcomeId><gtr:partnerContribution>Proteomic analysis to identify interaction partners with latency-associated HCMV genes</gtr:partnerContribution><gtr:piContribution>Analysis of the role of US28 and UL138-interacting proteins in HCMV latency</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johannes Gutenberg University of Mainz</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute for Virology</gtr:department><gtr:description>Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus</gtr:description><gtr:id>20A0AD12-4395-47E9-82AE-3F7D4B0B5EA6</gtr:id><gtr:impact>Work was published in Virology &amp;quot;Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition&amp;quot; 2009</gtr:impact><gtr:outcomeId>DAqCyVEDrAT-1</gtr:outcomeId><gtr:piContribution>We generated human cytomegalovirus specific Cytotoxic CD8+ T cells which we then used in conjunction with mutant human cytomegaloviruses to further understand the contribution of US2 and US11 to MHC Class I immune evasion of CTL recognition.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infection and Population Health</gtr:department><gtr:description>Analysis of LUNA</gtr:description><gtr:id>403FE39F-FD22-4EFC-895D-DFF04EF03B26</gtr:id><gtr:impact>Reeves et al 2010. Human cytomegalovirus IE72 protein interacts with the transcriptional repressor hDaxx to regulate LUNA gene expression during lytic infection J. Virol 84:7185</gtr:impact><gtr:outcomeId>Ydz95qU4TtY-1</gtr:outcomeId><gtr:partnerContribution>co-analysers of the LUNA gene product</gtr:partnerContribution><gtr:piContribution>Analysis of the control of the HCMV latency-associated LUNA gene product of HCMV</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oral presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A3F9506D-B192-4ABC-AFCF-F86B5C0DEDF5</gtr:id><gtr:impact>University of Cambridge Science Festival

Dissemination of the research to the public</gtr:impact><gtr:outcomeId>ABE2AD9F7B1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Training Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6EB3EC18-5CBF-47BB-A5BF-B35910557054</gtr:id><gtr:outcomeId>tJq9rPvuBKS</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>86000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Tibotec Pharmaceuticals</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>Janssen Research &amp; Development</gtr:fundingOrg><gtr:id>AD77F20A-E093-4DB6-8975-5F115C431A97</gtr:id><gtr:outcomeId>NRYnExhJGWC0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaborative project with TIBOTEC Pharmaceuticals Ltd</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Janssen Research &amp; Development</gtr:fundingOrg><gtr:fundingRef>not known</gtr:fundingRef><gtr:id>6186A0A0-5BB5-4ADF-9019-2D00A839476D</gtr:id><gtr:outcomeId>fy6ZnwyrBzD0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K021087/1</gtr:fundingRef><gtr:id>5D419794-60BC-4FE1-B324-E059B888468C</gtr:id><gtr:outcomeId>FB3dqjpVP5N</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary award</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A947E6D8-CDAA-40DE-9A0F-893FCA058A9C</gtr:id><gtr:outcomeId>PWo7vFkh8Ng</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>293275</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Welcome Trust Funded 3 year project grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>094107/Z/10/Z</gtr:fundingRef><gtr:id>D63D0B3C-5C0D-4AE4-9096-7DD8EF81CF9D</gtr:id><gtr:outcomeId>Y9WiXezQ1JW</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Welcome Trust funded 4 year PhD project</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8030B971-4D1D-427E-A057-6327C0673B4F</gtr:id><gtr:outcomeId>UH7dyVrRW54</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Doctoral training grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D49F9801-A4A7-442E-8116-6EDFDB2B2AEA</gtr:id><gtr:outcomeId>pbYU9fZhHWf</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Doctoral training grant</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>82330183-E19D-4CE3-9B53-4E210F166581</gtr:id><gtr:outcomeId>nva7sWakHot</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome PhD award (Infection and Immunity)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>549907F2-DD83-4055-9C8A-A37D71EE7A3D</gtr:id><gtr:outcomeId>rHFjt6zrYmn</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Non-immunogenic therapeutic anti-apoptotic RNA molecule</gtr:description><gtr:grantRef>G0701279</gtr:grantRef><gtr:id>96872D37-2C64-4568-BAD2-63518D14CEC3</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>AFiaZAGNeXt</gtr:outcomeId><gtr:patentId>GB0809476.5</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Non-immunogenic therapeutic anti-apoptotic RNA molecule</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>DETECTION AND DEPLETION OF HCMV INFECTED CELLS</gtr:description><gtr:grantRef>G0701279</gtr:grantRef><gtr:id>E5A54CC0-334B-4783-A960-8B8FAF50B7A9</gtr:id><gtr:impact>This is a proof of principle that latent HCMC infection could be targeted therapeutically</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>544e0aa7e63231.21895016</gtr:outcomeId><gtr:patentId>WO/2012/156733</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>DETECTION AND DEPLETION OF HCMV INFECTED CELLS</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The ability to target and kill HCMV infected cells</gtr:description><gtr:grantRef>G0701279</gtr:grantRef><gtr:id>6BB4DB20-F39F-45F1-8B46-DB320F9595D3</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>aCJpaULdexZ</gtr:outcomeId><gtr:patentId>WO2012156733</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Detection and depletion of HCMV infected cells</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Recombinant viral mutants deficient in latent gene expression</gtr:description><gtr:id>5113CB6A-D8FE-4CF3-9A6D-09DDDA63A0F0</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:outcomeId>640553AEB7B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mutant viruses</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>CD34+ progenitor cells latently infected with cytomegalovirus</gtr:description><gtr:id>610408FC-6AD8-4E49-BD0B-379AB41BE8CE</gtr:id><gtr:impact>Other research groups are using thsi model system</gtr:impact><gtr:outcomeId>168582D9163</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Model sysytems for cytomegalovirus latency</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New targets to detect latently infected cells by PCR</gtr:description><gtr:id>A55DE5F1-56FD-4C6D-8030-360E56D88F1F</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:outcomeId>0B6F5DC0559</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Novel detection systems for latent infection</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BADEF634-8AB1-433E-A2D7-EDB34CF61361</gtr:id><gtr:title>Chromatin structure regulates human cytomegalovirus gene expression during latency, reactivation and lytic infection.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880c79b4b226cab99274f0fae7128192"><gtr:id>880c79b4b226cab99274f0fae7128192</gtr:id><gtr:otherNames>Sinclair J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>C466288D864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33FF7E1B-F2B1-4BEA-A8D7-5E3A4B0A4895</gtr:id><gtr:title>Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4eba9249e5210879c5ba825b58c879"><gtr:id>be4eba9249e5210879c5ba825b58c879</gtr:id><gtr:otherNames>Mason GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_12893_23_22826250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B4DB856-C574-4512-9E91-DFF61AC7DBE3</gtr:id><gtr:title>Depletion of cellular pre-replication complex factors results in increased human cytomegalovirus DNA replication.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fb9a53ac3ff5ecb2d97e2de7a0894de"><gtr:id>1fb9a53ac3ff5ecb2d97e2de7a0894de</gtr:id><gtr:otherNames>Braun TE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12893_23_22586460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA7C8A15-A9BB-4DDD-B743-9E22D24F210E</gtr:id><gtr:title>Natural killer cell evasion by an E3 ubiquitin ligase from Kaposi's sarcoma-associated herpesvirus.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20d02bc2c32cfe6f4c97355b57afcfe4"><gtr:id>20d02bc2c32cfe6f4c97355b57afcfe4</gtr:id><gtr:otherNames>Thomas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_12893_13_18481981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71121F81-C3CF-4D4B-939A-DA15DB51BDE9</gtr:id><gtr:title>The cellular protein MCM3AP is required for inhibition of cellular DNA synthesis by the IE86 protein of human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_12893_23_23094019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0CC051A-4EAB-4A8D-A20A-7640C2C8AD5B</gtr:id><gtr:title>Human cytomegalovirus IE72 protein interacts with the transcriptional repressor hDaxx to regulate LUNA gene expression during lytic infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04c8cc419a2f3be17568a098587458a0"><gtr:id>04c8cc419a2f3be17568a098587458a0</gtr:id><gtr:otherNames>Reeves M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>RGrzJADJKv6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6030D0B-23B0-462C-B492-1A994680E7BF</gtr:id><gtr:title>Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1fa95512c8c24498210be8597cb0d8"><gtr:id>6f1fa95512c8c24498210be8597cb0d8</gtr:id><gtr:otherNames>Reeves MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>gZLTnMZ8VYo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A80553A0-8C9D-4F83-A74E-31243B86899C</gtr:id><gtr:title>Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1fa95512c8c24498210be8597cb0d8"><gtr:id>6f1fa95512c8c24498210be8597cb0d8</gtr:id><gtr:otherNames>Reeves MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12893_23_23885077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FD21625-78A5-4961-891D-8EC9FEA2F44F</gtr:id><gtr:title>Cytomegalovirus beta2.7 RNA transcript protects endothelial cells against apoptosis during ischemia/reperfusion injury.</gtr:title><gtr:parentPublicationTitle>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11e74e5a3a7b3794a49aa81194f3c27f"><gtr:id>11e74e5a3a7b3794a49aa81194f3c27f</gtr:id><gtr:otherNames>Zhao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1053-2498</gtr:issn><gtr:outcomeId>iF9oJtLbv9o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A23AA926-C85E-4424-9014-6590787B82CD</gtr:id><gtr:title>The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12893_23_23365437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF672DF0-1B16-46FD-A5D1-BB95EE8F0B81</gtr:id><gtr:title>Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>3BB6FD58C82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75F0AB22-7C0E-4359-A170-BB56E531C62C</gtr:id><gtr:title>Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific &amp;quot;effector memory&amp;quot; (CD28(-) CD45RA(HI)) CD8(+) T cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e01291574513b806263a474c2963389e"><gtr:id>e01291574513b806263a474c2963389e</gtr:id><gtr:otherNames>Waller EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>7CD8BE4F7AD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A161C36-EF86-491C-9728-C9A8AB2174D8</gtr:id><gtr:title>Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34? progenitors.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>iwJAJKEFRKb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1A0338C-E700-4740-9F01-9B9E54E76402</gtr:id><gtr:title>Regulation of human cytomegalovirus transcription in latency: beyond the major immediate-early promoter.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04c8cc419a2f3be17568a098587458a0"><gtr:id>04c8cc419a2f3be17568a098587458a0</gtr:id><gtr:otherNames>Reeves M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>pm_12893_23_23736881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F7C51B1-5DB8-4E50-870B-39883100E410</gtr:id><gtr:title>Lytic infection of permissive cells with human cytomegalovirus is regulated by an intrinsic 'pre-immediate-early' repression of viral gene expression mediated by histone post-translational modification.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f06bcf853a3b3f2f7c17989d10224b85"><gtr:id>f06bcf853a3b3f2f7c17989d10224b85</gtr:id><gtr:otherNames>Groves IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>A3D71290BAA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>800435E0-6AF3-4734-9FD4-93F04747A037</gtr:id><gtr:title>Aspects of human cytomegalovirus latency and reactivation.</gtr:title><gtr:parentPublicationTitle>Current topics in microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04c8cc419a2f3be17568a098587458a0"><gtr:id>04c8cc419a2f3be17568a098587458a0</gtr:id><gtr:otherNames>Reeves M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0070-217X</gtr:issn><gtr:outcomeId>pm_12893_13_18637513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F40279A-601E-4C1F-AD41-02D5CEA14A88</gtr:id><gtr:title>Human cytomegalovirus gene UL76 induces IL-8 expression through activation of the DNA damage response.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76685e447641d3db3472055633f2342d"><gtr:id>76685e447641d3db3472055633f2342d</gtr:id><gtr:otherNames>Costa H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_12893_23_24068928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB8B5680-E6BD-4B56-B1D6-96C9AF9636EB</gtr:id><gtr:title>Manipulation of dendritic cell functions by human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>Expert reviews in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880c79b4b226cab99274f0fae7128192"><gtr:id>880c79b4b226cab99274f0fae7128192</gtr:id><gtr:otherNames>Sinclair J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1462-3994</gtr:issn><gtr:outcomeId>DC8ED528C55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C12F3F6-47C4-492C-8259-EC1C95EF3045</gtr:id><gtr:title>Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b3bbe27015d9b0d2dedbe98dbf0e42a"><gtr:id>1b3bbe27015d9b0d2dedbe98dbf0e42a</gtr:id><gtr:otherNames>Ormiston ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_12893_23_22832786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68EEC9A8-AA4A-4738-8AE1-4B45D9BD44FB</gtr:id><gtr:title>Efficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/791088abb6d8f720eb8d8a2d54f14b85"><gtr:id>791088abb6d8f720eb8d8a2d54f14b85</gtr:id><gtr:otherNames>Huang MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12893_23_22647696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FEA65F0-86C4-4642-B686-CBD579D30E28</gtr:id><gtr:title>Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20d02bc2c32cfe6f4c97355b57afcfe4"><gtr:id>20d02bc2c32cfe6f4c97355b57afcfe4</gtr:id><gtr:otherNames>Thomas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_12893_13_18230726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>904C286A-EBCC-4134-8767-87A95D377974</gtr:id><gtr:title>Human cytomegalovirus immunity and immune evasion.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14b5466875d526da0c1bf7e2cb63a0d5"><gtr:id>14b5466875d526da0c1bf7e2cb63a0d5</gtr:id><gtr:otherNames>Jackson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>kza83WqNCdu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C105345-9596-4F73-A634-4A310EF2CF7F</gtr:id><gtr:title>Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/480571fcfa950c333146811874d42270"><gtr:id>480571fcfa950c333146811874d42270</gtr:id><gtr:otherNames>Bennett NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_12893_23_20530255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D7EEC18-180A-424E-BA0D-729A8FB5F9F3</gtr:id><gtr:title>NF-kappaB-mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>FFEEC880F45</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F768C8C0-52B2-4573-850C-7F2A1434D3D5</gtr:id><gtr:title>Human cytomegalovirus: Latency and reactivation in the myeloid lineage.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880c79b4b226cab99274f0fae7128192"><gtr:id>880c79b4b226cab99274f0fae7128192</gtr:id><gtr:otherNames>Sinclair J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn><gtr:outcomeId>6949B875C1C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45C4A5BB-DAE2-43F5-A175-44F606ABE47C</gtr:id><gtr:title>The co-speciation of human cytomegalovirus (HCMV) with its human host has enabled this human pathogen to evolve multiple mechanisms to allow it to be carried, generally sub-clinically, for the lifetime of the host in the face of a robust immune response. Preface.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bee66e5d800437620ae80666b3b0c95"><gtr:id>7bee66e5d800437620ae80666b3b0c95</gtr:id><gtr:otherNames>Wills M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>XxAF85TsKKF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07734ECC-2FDC-40B4-B40D-AB9A48E0220F</gtr:id><gtr:title>Inhibition of epidermal growth factor receptor (EGFR) expression by human cytomegalovirus correlates with an increase in the expression and binding of Wilms' Tumour 1 protein to the EGFR promoter.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df2cb9d1519b99ab8eccc7589d52df06"><gtr:id>df2cb9d1519b99ab8eccc7589d52df06</gtr:id><gtr:otherNames>Jafferji I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>51964360A3C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85789B58-8866-4DBE-B3FE-2CEED4ECBAAB</gtr:id><gtr:title>Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4? T cells.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4eba9249e5210879c5ba825b58c879"><gtr:id>be4eba9249e5210879c5ba825b58c879</gtr:id><gtr:otherNames>Mason GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_12893_23_24130479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F91CB755-F584-4696-8980-A2100BEB7420</gtr:id><gtr:title>Dynamics of T cell memory in human cytomegalovirus infection.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e01291574513b806263a474c2963389e"><gtr:id>e01291574513b806263a474c2963389e</gtr:id><gtr:otherNames>Waller EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>85B13ABB559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55A88504-3681-4E1B-A784-8FEB4D5C340E</gtr:id><gtr:title>The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbcad82585b37e480939c9b187de13c5"><gtr:id>fbcad82585b37e480939c9b187de13c5</gtr:id><gtr:otherNames>Cano F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_12893_23_22863774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>426CDC01-7CD7-478D-88FE-9E8C6771E0FA</gtr:id><gtr:title>A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93af7377184cdebbd9a735f34f7d49a3"><gtr:id>93af7377184cdebbd9a735f34f7d49a3</gtr:id><gtr:otherNames>Kuan WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_12893_23_22184634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A39F8663-96B3-4D09-BF5A-88FC9BA3BECD</gtr:id><gtr:title>Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd0fe58d15c91a83060bab38570801b7"><gtr:id>cd0fe58d15c91a83060bab38570801b7</gtr:id><gtr:otherNames>Besold K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>J4cPYt3PUKd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C75C332F-225E-4FF3-A3C3-47F0DC5D7376</gtr:id><gtr:title>Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b895d6f1022449850bff9b154540eb7"><gtr:id>6b895d6f1022449850bff9b154540eb7</gtr:id><gtr:otherNames>Weekes MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_12893_23_23580527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F1F7E90-FEE2-4B7C-BAE0-E8882AA302CC</gtr:id><gtr:title>Immunosenescence and Cytomegalovirus: where do we stand after a decade?</gtr:title><gtr:parentPublicationTitle>Immunity &amp; ageing : I &amp; A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3d7b94b96c564cc8d50398b265aff7d"><gtr:id>e3d7b94b96c564cc8d50398b265aff7d</gtr:id><gtr:otherNames>Pawelec G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1742-4933</gtr:issn><gtr:outcomeId>YFm3XbPFTid</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA5CEC55-BAF9-4130-B6D3-D9A27BD4278F</gtr:id><gtr:title>NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72bde0b23544f96ac8d87c98118e1b63"><gtr:id>72bde0b23544f96ac8d87c98118e1b63</gtr:id><gtr:otherNames>Ashiru O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_12893_13_19793804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CCD7759-FB10-4A14-9ABE-1B45F0A132E3</gtr:id><gtr:title>Report from the second cytomegalovirus and immunosenescence workshop.</gtr:title><gtr:parentPublicationTitle>Immunity &amp; ageing : I &amp; A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bee66e5d800437620ae80666b3b0c95"><gtr:id>7bee66e5d800437620ae80666b3b0c95</gtr:id><gtr:otherNames>Wills M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4933</gtr:issn><gtr:outcomeId>pm_12893_23_22035114</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701279</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>